The FDA approved Yescarta or axicabtagene ciloleucel, a cell-based gene therapy, on October 18, 2017, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment.Developed by Gilead's (GILD) subsidiary Kite Pharma Inc., Yescarta, a chimeric antigen receptor or CAR T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma.Diffuse large B-cell lymphoma or DLBCL is the most common type of NHL in adults. NHLs are cancers that begin in certain cells of the immune system and can be either fast-growing (aggressive) or slow-growing.Novartis' (NVS) Kymriah, approved, in August, for the treatment of relapsed B-cell precursor acute lymphoblastic leukemia, is the first ever CAR-T therapy to win a regulatory green light.Yescarta has a list price of $373,000, and Kymriah has a price tag of $475,000.